DiaMedica Q1 net loss $10M; cash $51.3M; ReMEDy2 >70% enrollment

DiaMedica Therapeutics Inc.

Net loss $10.0M in Q1 2026 vs $7.7M in Q1 2025; R&D expenses up to $8.0M from $5.7M.
Cash $51.3M as of March 31, 2026, down from $59.9M; company expects runway through 2027.
ReMEDy2 Phase 2/3 acute ischemic stroke trial surpassed 70% of required enrollment; interim analysis planned Q4 2026.
Preeclampsia Phase 2 IST expansion cohort enrolling; updated dataset expected in Q2 2026.
Rabbit study showed antibody response to DM199, preventing fetal development study; awaiting FDA response.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

DiaMedica Therapeutics Inc. reported the quarter ended March 31, 2026 results: net income Net loss was $10.0 million for the three months ended March 31, 2026, compared to $7.7 million for the three months ende.

Period: the quarter ended March 31, 2026
Net income: Net loss was $10.0 million for the three months ended March 31, 2026, compared to $7.7 million for the three months ende
Result: reported results

Exact text from the filing

Net loss was $10.0 million for the three months ended March 31, 2026, compared to $7.7 million for the three months ended March 31, 2025.

View on SEC.gov

8 earnings releases filed in the last 30 days. Browse all earnings releases →

DiaMedica Therapeutics Inc. filing history →

Source: SEC EDGAR

accession 0001437749-26-015218

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.